Loading...

FITC anti-human CD16 Antibody

Pricing & Availability
Clone
3G8 (See other available formats)
Regulatory Status
RUO
Workshop
V NK80
Other Names
FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
3G8_FITC_071805
Human peripheral blood lymphocytes stained with 3G8 FITC
  • 3G8_FITC_071805
    Human peripheral blood lymphocytes stained with 3G8 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
302005 25 tests 75€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302006 100 tests 187€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Capuchin Monkey, Chimpanzee, Common Marmoset, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human PMN cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
  4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
  5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
  6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
  7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
  8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
  9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
  10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed
  11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
  16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  18. Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations
  1. Sagnella SM, et al. 2020. Cancer Cell. 37(3):354-370. PubMed
  2. Okada T, et al. 2010. Am J Pathol. 176:2309. PubMed
  3. Babania O, et al. 2021. J Clin Lab Anal. 35:e23984. PubMed
  4. Woan KV, et al. 2021. Cell Stem Cell. 28:2062. PubMed
  5. Sefik E, et al. 2022. Nature. 606:585. PubMed
  6. Saber MM, et al. 2022. J Immunol Res. 2022:7219207. PubMed
  7. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  8. Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed
  9. Rosendahl Huber A, et al. 2022. STAR Protoc. 3:101361. PubMed
  10. Brandsma AM, et al. 2021. Blood Cancer Discov. 2:484. PubMed
  11. Tripathi H, et al. 2020. J Mol Cell Cardiol. 149:95. PubMed
  12. Poonia B, Pauza C 2014. PLoS One. 9:88884. PubMed
  13. Tong M, et al. 2019. J Immunol. 203:500. PubMed
  14. Kerr SC, et al. 2020. Clin Exp Allergy. 50:904. PubMed
  15. Laustsen A, et al. 2021. Elife. 10:. PubMed
  16. Hasaart KAL, et al. 2020. Sci Rep. 10:12991. PubMed
  17. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  18. Søndergaard J, et al. 2014. Int Immunol. 26) : 705-16. PubMed
  19. Seamon K, et al. 2020. Front Immunol. 11:396. PubMed
  20. Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed
  21. Xu Y, et al. 2021. Stem Cell Res Ther. 12:112. PubMed
  22. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  23. Hunn M, et al. 2012. Clin Cancer Res. 18:6446. PubMed
  24. Wu HL, et al. 2018. J Immunol. 200:49. PubMed
  25. Wang Y, et al. 2019. J Transl Med. 17:93. PubMed
  26. Gärtner K, et al. 2018. Cancer Med. 11:39. PubMed
  27. Zhang D, et al. 2020. Oncoimmunology. 9:1744921. PubMed
  28. Tong M, et al. 2021. J Immunol. 206:1039. PubMed
  29. Brandsma AM, et al. 2021. Cancer Discov. . PubMed
  30. Wang H, et al. 2022. J Neuroinflammation. 19:171. PubMed
  31. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
  32. Yokoyama K, et al. 2022. Front Immunol. 13:1016914. PubMed
  33. Evans RDR, et al. 2020. Nat Commun. 3.491666667. PubMed
  34. Mulfaul K, et al. 2020. Cell Rep. 30:2209. PubMed
  35. Osorio FG et al. 2018. Cell reports. 25(9):2308-2316 . PubMed
  36. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  37. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  38. Ugawa M, et al. 2021. Elife. 10:. PubMed
  39. Fisch D, et al. 2022. Pathog Dis. 79:. PubMed
  40. Guo M, et al. 2021. Front Oncol. 11:632540. PubMed
  41. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  42. Zee BM, et al. 2021. iScience. 24(6):102651. PubMed
  43. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  44. Sefik E, et al. 2021. Nat Biotechnol. . PubMed
  45. Liu J, et al. 2022. iScience. 25:105509. PubMed
  46. Cheng Y, et al. 2021. Immunity. 54(8):1825-1840.e7. PubMed
  47. Hazenberg MD, et al. 2019. Blood Adv. 2.659722222. PubMed
  48. Ren C, et al. 2020. J Immunol. 204:1012. PubMed
  49. Tong M, et al. 2021. J Reprod Immunol. 145:103306. PubMed
  50. Yoshida R, et al. 2022. Cancer Res. :. PubMed
  51. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  52. Zhao NQ, et al. 2020. PLoS One. 15:e0238347. PubMed
  53. Xue D, et al. 2013. Transplant Proc. 45:3279. PubMed
  54. Pahl JHW, et al. 2018. Cancer Immunol Res. 0.609027778. PubMed
  55. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  56. Bal S, et al. 2016. Nat Immunol. 10.1038/ni.3444. PubMed
  57. Hasaart KAL, et al. 2022. iScience. 25:103736. PubMed
  58. Johnson RK, et al. 2022. Sci Rep. 12:19920. PubMed
  59. Reitinger C, et al. 2022. Front Immunol. 13:970290. PubMed
  60. Wells DK, et al. 2020. Cell. 183:818. PubMed
  61. Vanoni G, et al. 2021. eLife. 10:00. PubMed
  62. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  63. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
RRID
AB_314205 (BioLegend Cat. No. 302005)
AB_314205 (BioLegend Cat. No. 302006)

Antigen Details

Structure
Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution

NK cells, activated monocytes, macrophages, neutrophils

Function
Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor
Aggregated IgG, IgG-antigen complex
Cell Type
Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Antigen References

1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
2. Stroncek D, et al. 1991. Blood 77:1572.
3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.

Gene ID
2214 View all products for this Gene ID
UniProt
View information about CD16 on UniProt.org

Related FAQs

Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?

Yes

Other Formats

View All CD16 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD16 3G8 FC
Biotin anti-human CD16 3G8 FC
FITC anti-human CD16 3G8 FC
Brilliant Violet 711™ anti-human CD16 3G8 FC
PE anti-human CD16 3G8 FC
PE/Cyanine5 anti-human CD16 3G8 FC
Purified anti-human CD16 3G8 FC,CyTOF®,Block,IHC-F,IP,Stim
APC/Cyanine7 anti-human CD16 3G8 FC
PE/Cyanine7 anti-human CD16 3G8 FC
Alexa Fluor® 488 anti-human CD16 3G8 FC
Alexa Fluor® 647 anti-human CD16 3G8 FC
Pacific Blue™ anti-human CD16 3G8 FC
Alexa Fluor® 700 anti-human CD16 3G8 FC
PerCP/Cyanine5.5 anti-human CD16 3G8 FC
PerCP anti-human CD16 3G8 FC
Brilliant Violet 421™ anti-human CD16 3G8 FC
Brilliant Violet 570™ anti-human CD16 3G8 FC
Brilliant Violet 605™ anti-human CD16 3G8 FC
Brilliant Violet 650™ anti-human CD16 3G8 FC
Brilliant Violet 785™ anti-human CD16 3G8 FC
Brilliant Violet 510™ anti-human CD16 3G8 FC
Ultra-LEAF™ Purified anti-human CD16 3G8 FC,CyTOF®,Block,IHC-F,IP,Stim
Purified anti-human CD16 (Maxpar® Ready) 3G8 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD16 3G8 FC
APC/Fire™ 750 anti-human CD16 3G8 FC
PE anti-human CD16 3G8 FC
APC anti-human CD16 3G8 FC
Pacific Blue™ anti-human CD16 3G8 FC
PE/Dazzle™ 594 anti-human CD16 3G8 FC
TotalSeq™-A0083 anti-human CD16 3G8 PG
TotalSeq™-B0083 anti-human CD16 3G8 PG
TotalSeq™-C0083 anti-human CD16 3G8 PG
PE/Cyanine7 anti-human CD16 3G8 FC
PE/Fire™ 640 anti-human CD16 3G8 FC
FITC anti-human CD16 3G8 FC
Spark YG™ 581 anti-human CD16 3G8 FC
APC/Fire™ 750 anti-human CD16 3G8 FC
TotalSeq™-D0083 anti-human CD16 3G8 PG
APC/Fire™ 810 anti-human CD16 3G8 FC
GMP APC anti-human CD16 3G8 FC
GMP PE/Dazzle™ 594 anti-human CD16 3G8 FC
GMP PE anti-human CD16 3G8 FC
Spark Red™ 718 anti-human CD16 3G8 FC
GMP Pacific Blue™ anti-human CD16 3G8 FC
GMP FITC anti-human CD16 3G8 FC
Spark Blue™ 515 anti-human CD16 3G8 FC
Spark UV™ 387 anti-human CD16 3G8 FC
PerCP/Cyanine5.5 anti-human CD16 3G8 FC
GMP PE/Cyanine7 anti-human CD16 3G8 FC
GMP APC/Fire™ 750 anti-human CD16 3G8 FC
Brilliant Violet 750™ anti-human CD16 3G8 FC
Spark Blue™ 550 anti-human CD16 3G8 FC
GMP PerCP/Cyanine5.5 anti-human CD16 3G8 FC
Spark YG™ 593 anti-human CD16 3G8 FC
Spark NIR™ 685 anti-human CD16 3G8 FC
Spark Violet™ 500 anti-human CD16 3G8 FC
Spark Blue™ 574 anti-human CD16 (Flexi-Fluor™) 3G8 FC
Spark PLUS UV395™ anti-human CD16 3G8 FC
Go To Top Version: 2    Revision Date: 05.23.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account